Drug Profile
Research programme: peptides therapeutics - Interprotein/Ipsen
Latest Information Update: 25 Aug 2023
Price :
$50
*
At a glance
- Originator Interprotein Corporation; Ipsen
- Class Peptides; Proteins
- Mechanism of Action Immunomodulators; Peptide modulators; Protein-protein interaction inhibitors; Protein-protein interaction modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Endocrine disorders
Most Recent Events
- 25 Aug 2023 Discontinued - Preclinical for Endocrine disorders in France (unspecified route) before August 2023
- 28 Dec 2019 No recent reports of development identified for preclinical development in Endocrine-disorders in France
- 30 Dec 2015 Ipsen and Interprotein agree to co-promote and co-develop peptide therapeutics in US for endocrine disorders